医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Avacta and Daewoong Pharmaceutical Form Immunotherapy Focused Joint Venture

2020年01月08日 PM06:24
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, England & SEOUL, South Korea

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and Daewoong Pharmaceutical Co. Ltd., (KSX: 069620), a leading Korean pharmaceutical company, are pleased to announce that they have agreed to establish a joint venture in South Korea, and to enter a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.

Mesenchymal stem cells (MSCs) are promising agents for the treatment of autoimmune and inflammatory diseases. The joint venture will develop a new class of MSCs that are primed to produce Affimer proteins, which are designed to enhance the immune-modulatory effect when administered to patients, by reducing inflammatory or autoimmune responses.

Daewoong will provide the joint venture with access to its proprietary technology for generating allogeneic MSCs from a single donor to treat a large number of patients. This proprietary technology facilitates developing cell therapies as “off-the-shelf” products.

Avacta will develop Affimer proteins against several undisclosed targets which will be transferred to the joint venture to be incorporated into MSCs. The resulting engineered MSCs will have broad ranging therapeutic utility, depending on the Affimer proteins’ intended therapeutic purposes.

Avacta’s research and development costs will be fully covered by the joint venture and Avacta retains the rights to commercialise the Affimer proteins outside of the field of cell therapies. Avacta’s shareholding in the joint venture is 45% with Daewoong holding 55%, and the joint venture will be operationally managed by Seng-ho Jeon, CEO of Daewoong, with a Board composed of representatives of both Avacta (Alastair Smith, CEO and Matthew Vincent, VP Business Development and Strategy) and Daewoong.

Our partnership reinforces the shared vision of both companies to design the next level of treatment paradigm, and to open up a new horizon in immunotherapeutic strategies”, said Seng-ho Jeon.This innovative collaboration will deliver invaluable synergy and lead to new solutions with the potential to transform patients’ lives.”

We are very excited to establish the joint venture with Daewoong, a world-class partner, combining our powerful Affimer platform with MSCs to develop breakthrough medicines targeting immune-mediated diseases”, said Dr Alastair Smith, CEO of Avacta. “Affimer proteins have the potential to selectively modulate signalling pathways in inflammatory diseases in order to reduce the aberrant immune response occurring in those tissues, as well as positively impacting tissue regenerative pathways meant to repair and restore normal function to the affected tissues. We look forward to working closely with the Daewoong team to advance these promising therapeutics, and get them to the patients who need them.”

About Avacta Group plc - https://www.avacta.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005298/en/

CONTACT

Zyme Communications

Katie Odgaard

Tel: +44 (0)7787 502 947

katie.odgaard@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • JEOL:发布新的扫描电子显微镜JSM-IT700HR
  • Asahi Kasei Providing Samples of Hyaluronic Acid Nanogel as a New Pharmaceutical Excipient
  • PHC株式会社:オンライン資格確認へ対応する、PHCの医療機関・保険薬局向け医事コンピューターとパナソニックの「顔認証付きカードリーダー(マイナンバーカード対応)」とのシステム連携について
  • Evaluate新レポート:COVID-19パンデミック下でさえ、革新的で有効な治療薬に対する需要は続く
  • Cellix Bio Pharma Completes the Acquisition of Avaca Pharma